28 May 2021 14:24
Share Option Award
Oxford, U.K. 28 May 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the UK Clinical AI company, today announces the grant of options over 829,207 new ordinary shares of ten pence nominal value ("Ordinary Shares") on 28 May 2021 to certain employees and contractors in line with the terms of the Sensyne Health Share Option Plan 2018.
The share options have an exercise price of 156 pence per Ordinary Share and represents the mid-market closing price of the Ordinary Shares on 27 May 2021. The options will vest in three equal tranches on an annual basis from 28 May 2022 and will vest in full and only become eligible for exercise from 28 May 2024.
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer |
|
Dr Richard Pye, Chief Financial Officer
|
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+ 44 (0) 20 7418 8900 |
Dr Christopher Golden |
|
James Steel |
|
Victoria Erskine |
|
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma |
|
Euan Brown |
|
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Mary-Jane Elliott |
|
Jessica Hodgson |
|
Davide Salvi |
|
About Sensyne Health:
Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real-time decision-making systems for healthcare organizations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information visit www.sensynehealth.com.